**OPENING SOON**

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

UCI 14-25
Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)

UCI 15-79
Ph II Open-Label Randomized Radiosurgery w/ or w/o TT Fields for 1-10 Brain Metastases from NSCLC (Carrillo)

UC 16-01
Pathway Analyses for Individualized Network Therapeutics for Cancer (Ou)

LUNG CANCER

- **BLOOD DRAW ONLY**
- **DIAGNOSTIC**
- **NEW DX OF BRAIN METS**
- **FAILED PLATINUM-BASED CHEMO TX**
- **1ST LINE THERAPEUTIC**
For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu
Lung Cancer Clinical Trials

Multiple Mutations

**UCI 17-83**
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (Ou)

**UCI 13-49**
Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies (Ou)

**UCI 15-74**
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Seery)

**UCI 15-82**
A phase II, multicenter, four-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease (Ou)

ECOG-EAY131
Molecular Analysis for Therapy Choice (MATCH) (Seery)

**UCI 16-79**
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harbor All ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) (Ou)

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

**OPENING SOON**